ARCHIVES

Extent Of Risk Reduction From Ovary Removal Varies According To BRCA Mutation

This article is from The Cancer Letter archive.

Vol. 31 No. 2 | February 29, 2008

Download PDF Visit The Full Archive

Related Articles

FDA cancer therapeutics review split among three units in reorganization.

October 10, 2003

In Brief: David Tweardy named head of internal medicine at MD Anderson

September 19, 2014

Obama Signs Bill Giving FDA Authority Over Tobacco Products

June 26, 2009

Wilding named director, Univ. of Wisconsin Cancer Center.

January 30, 2004

FDA Advisory Committee To Consider NDAs On Novantrone, HD MTX

November 27, 1987

713 Nurses Pass Certification exam At ONS Congress

July 8, 1988